180 Life Sciences

180 Life Sciences

Biotechnology, 150 W 56th St, New York, 10019, United States, 1-10 Employees

180lifesciences.com

  • facebook
  • twitter
  • instagram
  • LinkedIn

Who is 180 LIFE SCIENCES

180 Life Sciences Corp. (NASDAQ: ATNF) is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and ...

Read More

map
  • 150 W 56th St, New York, New York, 10019, United States Headquarters: 150 W 56th St, New York, New York, 10019, United States
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $5 Million to $10 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from 180 LIFE SCIENCES

180 Life Sciences Org Chart and Mapping

Employees

Jonathan Rothbard

Founder and Chief Scientific Officer 180 Life Sciences

Valerie Diemdowicz

Senior Executive Assistant (Remote)

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding 180 Life Sciences

Answer: 180 Life Sciences's headquarters are located at 150 W 56th St, New York, 10019, United States

Answer: 180 Life Sciences's official website is https://180lifesciences.com

Answer: 180 Life Sciences's revenue is $5 Million to $10 Million

Answer: 180 Life Sciences's SIC: 2834

Answer: 180 Life Sciences has 1-10 employees

Answer: 180 Life Sciences is in Biotechnology

Answer: 180 Life Sciences contact info: Phone number: Website: https://180lifesciences.com

Answer: 180 Life Sciences Corp. (NASDAQ: ATNF) is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the worlds biggest drivers of disease inflammation. The Company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Companys primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor).

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access